𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Frontline: Neuropilin-1: a surface marker of regulatory T cells

✍ Scribed by Dunja Bruder; Michael Probst-Kepper; Astrid M. Westendorf; Robert Geffers; Stefan Beissert; Karin Loser; Harald von Boehmer; Jan Buer; Wiebke Hansen

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
201 KB
Volume
34
Category
Article
ISSN
0014-2980

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

CD4^+^CD25^+^ regulatory T cells (T~reg~ cells) control immune responsiveness to a large variety of antigens. The isolation and therapeutic manipulation of T~reg~ cells requires the use of reliable surface receptors that are selectively up‐regulated in T~reg~ cells. On the basis of global gene expression studies, we identified neuropilin‐1 (Nrp1) as a specific surface marker for CD4^+^CD25^+^ T~reg~ cells. Nrp1, a receptor involved in axon guidance, angiogenesis, and the activation of T cells, is constitutively expressed on the surface of CD4^+^CD25^+^ T~reg~ cells independently of their activation status. In contrast, Nrp1 expression is down‐regulated in naive CD4^+^CD25^–^ T cells after TCR stimulation. Furthermore, CD4^+^Nrp1^high^ T cells express high levels of Foxp3 and suppress CD4^+^CD25^–^ T cells. Thus, Nrp1 constitutes a useful surface marker to distinguish T~reg~ cells from both naive and recently activated CD4^+^CD25^+^ non‐regulatory T cells.

📜 SIMILAR VOLUMES

NKG2A is a marker for acquisition of reg
NKG2A is a marker for acquisition of regulatory function by human CD8+ T cells activated with anti-CD3 antibody
✍ Vitaly Ablamunits; Octavian Henegariu; Paula Preston-Hurlburt; Kevan C. Herold 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB 👁 1 views

## Abstract Treatment with anti‐CD3 mAb modulates immune responses that cause type 1 diabetes and other diseases. CD8^+^ Tregs can be induced in vitro and in vivo by mAb. However, 1/3 of patients do not respond to drug therapy and in an equal proportion, anti‐CD3 mAb does not induce Tregs in vitro.

VLA-1: a T cell surface antigen which de
VLA-1: a T cell surface antigen which defines a novel late stage of human T cell activation
✍ Martin E. Hemler; Jennie G. Jacobson; Michael B. Brenner; Dean Mann; Jack L. Str 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 809 KB

## VLA-1: a T cell surface antigen which defines a novel late stage of human T cell activation* The VLA-1 protein complex defines a previously undescribed very late stage of activated T cell differentiation, following either alloantigen or mitogen activation. This protein appears after 2-3 weeks o

Regulatory T cells enter the pancreas du
Regulatory T cells enter the pancreas during suppression of type 1 diabetes and inhibit effector T cells and macrophages in a TGF-β-dependent manner
✍ Daniel R. Tonkin; Kathryn Haskins 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 364 KB

## Abstract Treg can suppress autoimmune diseases such as type 1 diabetes, but their __in vivo__ activity during suppression remains poorly characterized. In type 1 diabetes, Treg activity has been demonstrated in the pancreatic lymph node, but little has been studied in the pancreas, the site of a